These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32384033)

  • 1. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
    Kiguchi N; Ding H; Kishioka S; Ko MC
    Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
    Kiguchi N; Ding H; Ko MC
    J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
    Kiguchi N; Kishioka S; Ko MC
    Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.
    Kiguchi N; Ding H; Cami-Kobeci G; Sukhtankar DD; Czoty PW; DeLoid HB; Hsu FC; Toll L; Husbands SM; Ko MC
    Br J Anaesth; 2019 Jun; 122(6):e146-e156. PubMed ID: 30916003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
    Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
    Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of NOP-Related Ligands in Nonhuman Primates.
    Kiguchi N; Ko MC
    Handb Exp Pharmacol; 2019; 254():323-343. PubMed ID: 30879202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central N/OFQ-NOP Receptor System in Pain Modulation.
    Kiguchi N; Ding H; Ko MC
    Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
    Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
    J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
    Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
    Lin AP; Ko MC
    ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
    Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
    Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
    Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
    Cremeans CM; Gruley E; Kyle DJ; Ko MC
    J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM; Rutten K
    Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics.
    Dasgupta P; Mann A; Polgar WE; Reinscheid RK; Zaveri NT; Schulz S
    Sci Rep; 2022 May; 12(1):7154. PubMed ID: 35504962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.
    Schröder W; Lambert DG; Ko MC; Koch T
    Br J Pharmacol; 2014 Aug; 171(16):3777-800. PubMed ID: 24762001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
    Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Jansen U; Christoph T
    Eur J Pharmacol; 2018 Aug; 832():90-95. PubMed ID: 29753041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
    Coluzzi F; Rullo L; Scerpa MS; Losapio LM; Rocco M; Billeci D; Candeletti S; Romualdi P
    CNS Drugs; 2022 Jun; 36(6):617-632. PubMed ID: 35616826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.